000285014 001__ 285014
000285014 005__ 20260203102555.0
000285014 0247_ $$2doi$$a10.1111/bpa.70044
000285014 0247_ $$2pmid$$apmid:41033666
000285014 0247_ $$2pmc$$apmc:PMC12861568
000285014 0247_ $$2ISSN$$a1015-6305
000285014 0247_ $$2ISSN$$a1750-3639
000285014 037__ $$aDZNE-2026-00140
000285014 041__ $$aEnglish
000285014 082__ $$a610
000285014 1001_ $$00000-0001-7523-6622$$aFranz, Jonas$$b0
000285014 245__ $$a3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale x-ray phase-contrast tomography.
000285014 260__ $$aOxford$$bWiley-Blackwell$$c2026
000285014 3367_ $$2DRIVER$$aarticle
000285014 3367_ $$2DataCite$$aOutput Types/Journal article
000285014 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770110654_10795
000285014 3367_ $$2BibTeX$$aARTICLE
000285014 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285014 3367_ $$00$$2EndNote$$aJournal Article
000285014 520__ $$aThis study leverages x-ray phase-contrast tomography (XPCT) for detailed analysis of neurodegenerative diseases, focusing on the three-dimensional (3D) visualization and quantification of neuropathological features within fixed human postmortem tissue. XPCT with synchrotron radiation offers micrometer and even sub-micron resolution, enabling us to examine intra- and extraneuronal aggregates and inclusions such as Lewy bodies (LBs), granulovacuolar degeneration (GvD), Hirano bodies (HBs), neurofibrillary tangles (NFTs), β-amyloid plaques, and vascular amyloid deposits in three dimensions. In the reconstructions, we identified the highest electron densities in Hirano and LBs, while NFTs exhibited no significant increase in XPCT contrast. Using cutting-edge high-resolution x-ray synchrotron beamlines, we were now able to detect even detect subcellular differences in electron densities found in GvD. Small-scale inhomogeneities of the electron density were also detected in LBs, potentially relating to inclusions of organelles. Additionally, we reveal here a peculiar 3D geometry of HBs and demonstrate the co-occurrence with GvD in the same neuron. These findings underscore the potential of XPCT as a powerful, label-free tool for spatially resolved neuropathological investigations, opening new avenues for the systematic 3D characterization of inclusions and aggregates in neurodegeneration.
000285014 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000285014 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285014 650_7 $$2Other$$aLewy bodies
000285014 650_7 $$2Other$$aneurodegeneration
000285014 650_7 $$2Other$$aneuroimaging
000285014 650_7 $$2Other$$aprotein aggregates
000285014 650_7 $$2Other$$asynchrotron radiation
000285014 650_7 $$2Other$$ax‐ray phase‐contrast tomography
000285014 650_7 $$2NLM Chemicals$$aProtein Aggregates
000285014 650_2 $$2MeSH$$aHumans
000285014 650_2 $$2MeSH$$aImaging, Three-Dimensional: methods
000285014 650_2 $$2MeSH$$aNeurodegenerative Diseases: pathology
000285014 650_2 $$2MeSH$$aNeurodegenerative Diseases: diagnostic imaging
000285014 650_2 $$2MeSH$$aInclusion Bodies: pathology
000285014 650_2 $$2MeSH$$aAged
000285014 650_2 $$2MeSH$$aNeurons: pathology
000285014 650_2 $$2MeSH$$aFemale
000285014 650_2 $$2MeSH$$aMale
000285014 650_2 $$2MeSH$$aAged, 80 and over
000285014 650_2 $$2MeSH$$aProtein Aggregates: physiology
000285014 650_2 $$2MeSH$$aBrain: pathology
000285014 650_2 $$2MeSH$$aBrain: diagnostic imaging
000285014 650_2 $$2MeSH$$aNeurofibrillary Tangles: pathology
000285014 650_2 $$2MeSH$$aLewy Bodies: pathology
000285014 7001_ $$aReichmann, Jakob$$b1
000285014 7001_ $$aEckermann, Marina$$b2
000285014 7001_ $$aWürfel, Thea$$b3
000285014 7001_ $$aGroh, Artur$$b4
000285014 7001_ $$aQadri, Syed Fatima$$b5
000285014 7001_ $$aSchulz, Katja$$b6
000285014 7001_ $$0P:(DE-2719)9001340$$aMollenhauer, Brit$$b7$$udzne
000285014 7001_ $$aStadelmann, Christine$$b8
000285014 7001_ $$aSalditt, Tim$$b9
000285014 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.70044$$gVol. 36, no. 2, p. e70044$$n2$$pe70044$$tBrain pathology$$v36$$x1015-6305$$y2026
000285014 8564_ $$uhttps://pub.dzne.de/record/285014/files/DZNE-2026-00140.pdf$$yRestricted
000285014 8564_ $$uhttps://pub.dzne.de/record/285014/files/DZNE-2026-00140.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285014 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001340$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000285014 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000285014 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-10$$wger
000285014 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2022$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:07:24Z
000285014 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:07:24Z
000285014 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-08-08T17:07:24Z
000285014 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2022$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-10
000285014 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-10
000285014 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000285014 980__ $$ajournal
000285014 980__ $$aEDITORS
000285014 980__ $$aVDBINPRINT
000285014 980__ $$aI:(DE-2719)1410002
000285014 980__ $$aUNRESTRICTED